Bios I Pharma ApS

APSActive

CVR 32672620Palle Juul-Jensens Boulevard 82, 8200 Aarhus NResearch and experimental development on natural sciences and engineering· NACE 7210Est. 2010 · 16 years old— employees

Overview

Bios I Pharma ApS is a Danish APS based in Aarhus N, operating in the Research and experimental development on natural sciences and engineering sector. Incorporated in 2010, the company reported a gross profit of -DKK 68.1k in its latest annual filing.

Gross profit 2025

-0.1M DKK

−103% vs 2024

EBITDA margin (of gross profit)

100.0 %

−103% vs 2024

Net profit 2025

0.2M DKK

-88% vs 2024

Key ratios

See full ratios →

11.6 %

Very weak

Among the 20% lowest rated companies in the industry

20212025

1.1×

Weak

Among the 30% lowest rated companies in the industry

20212025

5.4 %

Average

Around the average of companies in the same industry

20212025

EBITDA — year on year

DKK thousands

Key figures

Annual report 2025

Gross profit	-0.1M DKK	-103%
EBITDA	-0.1M DKK	-103%
Net profit	0.2M DKK	-88%
Total assets	3.8M DKK	-2%
Equity	0.4M DKK	+86%
Employees	—	—

Contact

Address

Palle Juul-Jensens Boulevard 82, 8200 Aarhus N

Phone

+45 3073 1077

hj@dkmiljo.dk

Risika for professionals

Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.

Visit risika.com

Financial development

In its most recent annual report (2025), Bios I Pharma ApS reported a gross profit of -DKK 68.1k, a decrease of 103% on the year before. The figures on this page draw on 5 annual filings covering 2021 to 2025. The bottom line showed a net profit of DKK 206.3k.

At the end of 2025, equity financed 11.6% of the balance sheet, and current assets covered short-term debt 1.1 times. Bios I Pharma ApS is one of 2 companies registered under Research and experimental development on natural sciences and engineering in Denmark.

Financials

Gross profit

DKK thousands

EBITDA

DKK thousands

Income statement

DKK thousands

Item	2025	2024	2023	2022	2021
Gross profit	-68	2,012	-1	48	1
Staff expenses	-0	-0	-0	-0	-0
EBITDA	-68	2,012	-1	48	1
Depreciation & amort.	-0	-0	-0	-0	-0
EBIT	-68	2,012	-1	48	1
Net financials	333	-55	353	-38	-88
Profit before tax	264	1,957	352	10	-87
Tax	58	225	-0	-0	-19
Net profit	206	1,732	352	10	-68

Get a credit rating – not just the numbers

Financial statements show the past. Risika gives you a score and a recommended credit limit, so you know what the numbers mean for your risk.

See the credit rating

Balance sheet

DKK thousands

Item	2025	2024	2023	2022	2021
Total assets	3,834	3,903	1,841	1,866	1,882
Equity	445	239	-2,994	-3,345	-3,355
Long-term debt	58	225	4,507	5,136	5,158
Short-term debt	3,331	3,439	328	75	79
Total debt	3,389	3,664	4,835	5,211	5,237

Financial ratios

5-year trend

EBITDA margin (of gross profit)

<−999 %

20212025

Equity ratio

11.6 %

Very weak

Among the 20% lowest rated companies in the industry

20212025

Return on equity

46.3 %

Strong

Among the 30% highest rated companies in the industry

20212025

Net profit margin (of gross profit)

>999 %

20212025

Asset turnover (of gross profit)

-0.02×

20212025

Debt / equity

7.61×

Very weak

Among the 10% lowest rated companies in the industry

20212025

Sector performance

22 of 28 ratios graded

28 financial ratios from the latest filing, each graded against companies in the same industry.

Profitability

Return on equity (ROE)Strong

Among the 30% highest rated companies in the industry

Net profit as a percentage of equity — the return the owners earned on their invested capital this year.

Return on assets (ROA)Average

Around the average of companies in the same industry

Net profit as a percentage of total assets — the return generated on the capital employed.

Return on net assets (RONA)Strong

Among the 30% highest rated companies in the industry

Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.

Basic earning power (BEP)Weak

Among the 40% lowest rated companies in the industry

EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.

Gross marginNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.

Operating marginNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.

Net profit marginNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

The profit for the year as a share of revenue — the company's ability to turn revenue into profit.

Capacity ratioNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.

Liquidity

Current ratioWeak

Among the 30% lowest rated companies in the industry

Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.

Quick ratioWeak

Among the 30% lowest rated companies in the industry

Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.

Cash ratioVery weak

Among the 20% lowest rated companies in the industry

Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.

Current assets to equityVery weak

Among the 10% lowest rated companies in the industry

Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.

Fixed assets to long-term capitalAverage

Around the average of companies in the same industry

Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.

Cash conversion ratioVery weak

Among the 10% lowest rated companies in the industry

Cash flow relative to profit — the ability to convert reported profits into accessible cash.

Debt & solvency

Solidity ratioVery weak

Among the 20% lowest rated companies in the industry

Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.

Debt ratioVery weak

Among the 20% lowest rated companies in the industry

Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.

Debt to equityVery weak

Among the 10% lowest rated companies in the industry

Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.

Liabilities to equityVery weak

Among the 10% lowest rated companies in the industry

Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.

Income to debtAverage

Around the average of companies in the same industry

Profit relative to debt — the ability to create earnings while operating with debt.

EBITDA to debtWeak

Among the 40% lowest rated companies in the industry

EBITDA relative to debt — how much operating earnings are available to service the debt.

Interest coverageWeak

Among the 30% lowest rated companies in the industry

The ability to pay the interest on the company's debt out of its earnings.

Interest rate on debtAverage

Around the average of companies in the same industry

Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.

Interest marginAverage

Around the average of companies in the same industry

The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.

Efficiency & development

Equity to contributed capitalAverage

Around the average of companies in the same industry

Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.

One-year change in equityVery strong

Among the 10% highest rated companies in the industry

The size of this year's increase or decrease in the company's equity.

One-year change in debtStrong

Among the 40% highest rated companies in the industry

The size of this year's increase or decrease in the company's debt.

Asset turnoverNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

Revenue relative to total assets — the ability to generate revenue from the asset base.

Inventory turnoverNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.

Annual reports & filings

Annual report 2025
Filed via CVR / Virk · Period 2024-10-01 – 2025-09-30
View PDF
Annual report 2024
Filed via CVR / Virk · Period 2023-10-01 – 2024-09-30
View PDF
Annual report 2023
Filed via CVR / Virk · Period 2022-10-01 – 2023-09-30
View PDF
Annual report 2022
Filed via CVR / Virk · Period 2021-10-01 – 2022-09-30
View PDF
Annual report 2021
Filed via CVR / Virk · Period 2020-10-01 – 2021-09-30
View PDF

People & ownership

Management

Actively employed in the business

Name	Role	Member since
Current (2)
LA Lars Aabo Founder	Founder	2010
HB Henrik Beier Jessen Management	Management	2025

Former (3)


HL Henrik Lasse Lindblad Management	Management	2011 – 2016
JH Jens Henrik Haaning Management	Management	2016 – 2017
MB Michael Bødker Friis Chief Executive Officer	Chief Executive Officer	2010 – 2011

Board of directors

Non-executive oversight

No data on file.

Shareholders

Active legal owners

Shareholder	Type	Ownership	Votes	Registered
Beier Holding ApS	Company	100%	100%	2018
FINANSMANAGEMENT ApS	Company	50–66.65%	50–66.65%	2016
AQ2 A/S	Company	50–66.65%	50–66.65%	2016

Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.

One in three Danish companies experiences fraud

Sound familiar? See how to strengthen your defences and catch suspicious changes in ownership and management in time.

See the fraud module

Related companies

Company hierarchy

Beier Holding ApS100%

FINANSMANAGEMENT ApS50%

AQ2 A/S50%

Bios I Pharma ApS (this company)

Board network connections

Board members of Bios I Pharma ApS also hold positions in 52 other companies.

Person	Role here	Other companies
Henrik Beier Jessen	Management	29 companiesMany roles
Jens Henrik Haaning	Management	12 companiesMany roles
Henrik Lasse Lindblad	Management	11 companiesMany roles

Frequently asked questions

What is the CVR number of Bios I Pharma ApS?

Bios I Pharma ApS is registered with CVR / Virk under CVR 32672620.

What is the gross profit of Bios I Pharma ApS?

Bios I Pharma ApS reported a gross profit of -DKK 68.1k in 2025.

Where is Bios I Pharma ApS headquartered?

Bios I Pharma ApS's registered address is Palle Juul-Jensens Boulevard 82.